Journals / İzmir Tepecik Eğitim Hastanesi Dergisi / 2021 / Cilt: 31 - Sayı: 3

The Impact of Chemotherapy on the EORTC QLQ-C30 and LC-13 Quality of Life Scales in Patients with Lung Cancer

Akciğer Kanserli Hastalarda Kemoterapinin EORTC QLQ-C30 ve LC-13 Yaşam Kalitesi Ölçeklerine Etkisi

Pages
344–354
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The assessment of physical, social and occupational functions and overall health status of the male patients was better than female.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: The concept of quality of life (QoL) in lung cancer includes many physical, psychological and social components.
📊
Key Findings & Data:Turkish versions of the EORTC QLQ-C30 and LC13 scales were used before every cycles.
💡
Conclusion & Impact:The assessment of physical, social and occupational functions and overall health status of the male patients was better than female.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: The concept of quality of life (QoL) in lung cancer includes many physical, psychological and social components. We aimed to assess the effect of chemotherapy (CT) on QoL of lung cancer patients using QoL scales. Methods: Fifty inoperable lung cancer patients who were newly diagnosed and taken into a CT plan were included. Patients were followed in terms of responsiveness and toxicity. Turkish versions of the EORTC QLQ-C30 and LC13 scales were used before every cycles. Results: The average age was 60.1 years. There was no difference between QoL and age/income levels. The assessment of physical, social and occupational functions and overall health status of the male patients was better than female. Overall health status without comorbidity was better in the first cycle CT. Chemotherapy led to deterioration in social functions and economic status together with increase in neuropathy, constipation and hair loss. Patients with complete or partial response to treatment were observed to have better physical, occupational, emotional, cognitive and social functions, economic status and overall health; less fatigue, pain, shortness of breath, neuropathy and better appetite. Toxicities were found to affect the QLQ C30 and LC13 scales adversely. Conclusion: Presence of comorbidity, low education levels, socioeconomic status and CT induced hematologic/ gastrointestinal toxicities are the major parameters affect QOL in lung cancer. Chemotherapy leads to deterioration in social functions, increase in adverse events as well as worsening in economic status. Radiologic complete or partial response and small cell carcinoma are states in which parameters of QoL are affected positively by chemotherapy.

Özet

Amaç: Akciğer kanseri hastalarında yaşam kalitesi kavramı; fiziksel, psikolojik ve sosyal olmak üzere pek çok komponenti içermektedir. Bu çalışmada akciğer kanserli hastalarda kemoterapinin yaşam kalitesi üzerine etkisinin yaşam kalitesi ölçekleri kullanılarak belirlenmesi amaçlanmıştır. Yöntem: Araştırmaya yeni tanı alan ve kemoterapi planlanan 50 inoperabl akciğer kanserli hasta alındı. Hastalar tedaviye yanıt ve toksisite yönünden izleme alındı. EORTC QLQ-C30 ve LC13 ölçeklerinin Türkçe sürümleri her siklus öncesi uygulandı. Bulgular: Yaş ortalaması 60.1 yıldı. Yaş ve gelir düzeyi ile yaşam kalitesi parametreleri arasında fark bulunmadı. Erkeklerin; fiziksel, sosyal ve uğraş fonksiyonlarının ve genel sağlık durumu değerlendirmesi kadınlara göre daha iyi idi. Komorbiditesi olmayanların, 1. Siklus KT’de genel sağlık durumu değerlendirmesi daha iyi idi. Kemoterapi ile sosyal fonksiyonlarda, ekonomik durumda kötüleşme, nöropati, kabızlık ve saç dökülmesinde artış saptandı. Tedaviye tam veya kısmi yanıt elde edilen hastaların, fiziksel, uğraş, duygusal, kavrama, sosyal fonksiyonlarının, ekonomik durumlarının ve genel durum değerlendirmesinin daha iyi olduğu, yorgunluk, ağrı, nefes darlığı, nöropatinin daha az olduğu ve iştahın daha iyi olduğu belirlendi. Toksisitelerin QLQ C30 ve LC13 ölçeklerini olumsuz yönde etkilediği görüldü. Sonuç: Akciğer kanserinde komorbidite varlığı, düşük eğitim düzeyi, sosyoekonomik durum ve kemoterapiye bağlı hematolojik/gastrointestinal toksisiteler yaşam kalitesini etkileyen en önemli parametrelerdir. Kemoterapi ile sosyal fonksiyonlar ve ekonomik parametrelerde kötüleşme ile birlikte yan etkilerde artış izlenmiştir. Radyolojik tam veya kısmi yanıt, küçük hücreli karsinom hücre tipi kemoterapi ile yaşam kalitesi parametrelerinin olumlu etkilendiği durumlardır.

🔖

Cite This Article

KÖMÜRCÜOĞLU, B., YALNIZ, E., ERBAYCU, A. E., KARAKURT, G., GÜVENÇLİ, M. (2022). The Impact of Chemotherapy on the EORTC QLQ-C30 and LC-13 Quality of Life Scales in Patients with Lung Cancer. İzmir Tepecik Eğitim Hastanesi Dergisi, Cilt: 31 - Sayı: 3, 344–354. https://ajindex.com/articles/558052

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Yang SC, Lai WW, Hsiue TR, et al. Health-related quality of life after first-line anti-cancer treatments for advanced non- small cell lung cancer in clinical practice. Qual Life Res. 2016
  2. [CrossRef] 2. Lee LJ, Chung CW, Chang YY, et al. Comparison of the quality of life between patients with non-small-cell lung cancer and healthy controls. Qual Life Res. 2011
  3. [CrossRef] 3. Mannion E, Gilmartin JJ, Donnellan P, Keane M, Waldron D. Effect of chemotherapy on quality of life in patients with non-small cell lung cancer. Support Care Cancer. 2014
  4. [CrossRef] 4. Gultekin Z, Pinar G, Pinar T, et al. Health-related quality of life and health care services expectations of the patients with lung cancer. Int J Hematol Oncol. 2008
  5. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012
  6. [CrossRef] 6. Pandey M. Sarita G. Devi N. Distress, anxiety, and depression in cancer patients undergoing chemotherapy. World J Surgical Oncology. 2006
  7. [CrossRef] 7. Dai YL, Yang CT, Chen KH, Tang ST. Changes in and determi- nants of quality of life in patients with advanced non-small- cell lung cancer undergoing ınitial chemotherapy. J Nurs Res. 2017
  8. 25(3):203-15. [CrossRef] 8. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ- C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993
  9. [CrossRef] 9. Oken MM, Creec RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982
  10. [CrossRef] 10. Yates JW, Chalmer B, McKegney FP. Evaluation of patients with advanced cancer using the Karnofsky performance sta- tus. Cancer. 1980
  11. [CrossRef] 11. Common Terminology Criteria for Adverse Events (CTCAE). US Departmant of Health and Human Services, National Cancer Institute. Version 4.03, Published: June 2010. 12. Guzelant A, Goksel T, Ozkok S. The European Organization for Research and Treatment of Cancer QLQ-30: an examination into the cultural validity and reliability of Turkish version of the EORTC QLQ-30. Eur J Cancer Care. 2004
  12. [CrossRef] 13. Vallières E, Shepherd FA, Crowley J, et al. The IASLC Lung Cancer Staging Project: proposals regarding the relevance of TNM